Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-48. (Canceled)

Claim 49. (currently amended) A method for treating Alzheimer's disease ~~a disease characterized by beta amyloid deposits in the brain~~ comprising administering to a patient an effective therapeutic amount of a ~~hydroxyethylene~~ compound of the formula



(XII)

where R_1 is:

(I) C_1-C_6 alkyl, unsubstituted or substituted with one, two or three C_1-C_3 alkyl, -F, -Cl, -Br, -I, -OH, -NH_2, -C≡N, -CF_3, or -N_3,

(II) -$(CH_2)_{1-2}$-S-CH_3,

(III) -CH_2-CH_2-S-CH_3,

(IV) -CH_2-(C_2-C_6 alkenyl) unsubstituted or substituted by one -F,

(V) -$(CH_2)_{0-3}$-($R_{1\text{-aryl}}$) where $R_{1\text{-aryl}}$ is phenyl, 1-naphthyl, 2-naphthyl, indanyl, indenyl, dihydronaphthyl, tetralinyl unsubstituted or substituted on the aryl ring with one or two of

the following substituents which can be the same or different:

(A) C_1-C_3 alkyl,

(B) $-CF_3$,

(C) -F, Cl, -Br and -I,

(D) C_1-C_3 alkoxy,

(E) $-O-CF_3$,

(F) $-NH_2$,

(G) -OH, or

(H) $-C\equiv N$,

(VI) $-(CH_2)_{n1}-(R_{1\text{-heteroaryl}})$ where n_1 is 0, 1, 2, or 3 and $R_{1\text{-heteroaryl}}$ is:

(A) pyridinyl,

(B) pyrimidinyl,

(C) quinolinyl,

(D) indenyl,

(E) indanyl,

(F) benzothiophenyl,

(G) indolyl,

(H) indolinyl,

(I) pyridazinyl,

(J) pyrazinyl,

(K) isoindolyl,

(L) isoquinolyl,

(M) quinazolinyl,

(N) quinoxalinyl,

(O) phthalazinyl,

(P) imidazolyl,

(Q) isoxazolyl,

(R) pyrazolyl,

(S) oxazolyl,

(T) thiazolyl,

(U) indolizinyl,

(V) indazolyl,

(W) benzothiazolyl,

(X) benzimidazolyl,

(Y) benzofuranyl,

(Z) furanyl,

(AA) thienyl,

(BB) pyrrolyl,

(CC) oxadiazolyl,

(DD) thiadiazolyl,

(EE) triazolyl,

(FF) tetrazolyl,

(GG) 1, 4-benzodioxan

(HH) purinyl,

(II) oxazolopyridinyl,

(JJ) imidazopyridinyl,

(KK) isothiazolyl,

(LL) naphthyridinyl,

(MM) cinnolinyl,

(NN) carbazolyl,

(OO) β-carbolinyl,

(PP) isochromanyl,

(QQ) chromanyl,

(RR) furazanyl,

(SS) tetrahydroisoquinoline,

(TT) isoindolinyl,

(UU) isobenzotetrahydrofuranyl,

(VV) isobenzotetrahydrothienyl,

(WW) isobenzothiophenyl,

(XX) benzoxazolyl, or

(YY) pyridopyridinyl,

where the $R_{1\text{-heteroaryl}}$ group is bonded to $-(CH_2)_{0-3}-$ by any ring atom of the parent $R_{N\text{-heteroaryl}}$ group substituted by hydrogen such that the new bond to the $R_{1\text{-heteroaryl}}$ group replaces the hydrogen atom and its bond, where heteroaryl is unsubstituted or substituted with one or two:

(1) C_1-C_3 alkyl,

(2) $-CF_3$,

(3) -F, Cl, -Br, or -I,

(4) C_1-C_3 alkoxy,

(5) $-O-CF_3$,

(6) $-NH_2$,

(7) -OH, or

(8) $-C\equiv N$,

with the proviso that when n_1 is zero $R_{1\text{-heteroaryl}}$ is not bonded to the carbon chain by nitrogen, or

(VII) $-(CH_2)_{n1}-(R_{1\text{-heterocycle}})$ where n_1 is as defined above and

$R_{1\text{-heterocycle}}$ is:

(A) morpholinyl,

(B) thiomorpholinyl,

(C) thiomorpholinyl S-oxide,

(D) thiomorpholinyl S,S-dioxide,

(E) piperazinyl,

(F) homopiperazinyl,

(G) pyrrolidinyl,

(H) pyrrolinyl,

(I) tetrahydropyranyl,

(J) piperidinyl,

(K) tetrahydrofuranyl, or

(L) tetrahydrothiophenyl,

where the $R_{1\text{-heterocycle}}$ group is bonded by any atom of the parent $R_{1\text{-heterocycle}}$ group substituted by hydrogen such that the new bond to the $R_{1\text{-heteroaryl}}$ group replaces the hydrogen atom and its bond, where heterocycle is unsubstituted or substituted with one or two:

(1) =O,

(2) C_1-C_3 alkyl,

(3) $-CF_3$,

(4) -F, Cl, -Br and -I,

(5) C_1-C_3 alkoxy,

(6) $-O-CF_3$,

(7) $-NH_2$,

(8) -OH, or

(9) -C≡N,

with the proviso that when n_1 is zero $R_{1\text{-heterocycle}}$ is not bonded to the carbon chain by nitrogen;

where R_2 is:

(I) -H,

(II) C_1-C_6 alkyl, or

(III) $-(CH_2)_{0\text{-}4}-R_{2\text{-}1}$ where $R_{2\text{-}1}$ is $(C_3\text{-}C_6)$cycloalkyl, $R_{1\text{-aryl}}$ or $R_{1\text{-heteroaryl}}$ where $R_{1\text{-aryl}}$ and $R_{1\text{-heteroaryl}}$ are as defined above,

where R_N is:

(I) $R_{N\text{-}1}$-X_N- where X_N is:

(A) -CO-,

(B) $-SO_2-$,

(C) $-(CR'R'')_{1\text{-}6}$ where R′ and R″ are the same or different and are -H or C_1-C_4 alkyl,

(D) $-CO-(CR'R'')_{1\text{-}6}-X_{N\text{-}1}$ where $X_{N\text{-}1}$ is -O-, -S- and -NR′R"- and where R′ and R″ are as defined above,

(E) a single bond;

where R_{N-1} is:

(A) R_{N-aryl} where R_{N-aryl} is phenyl, 1-naphthyl and 2-naphthyl unsubstituted or substituted with one, two, three or four of the following substituents which can be the same or different and are:

(1) C_1-C_6 alkyl,

(2) -F, -Cl, -Br, or -I,

(3) -OH,

(4) $-NO_2$,

(5) -CO-OH,

(6) -C≡N,

(7) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are:

(a) -H,

(b) -C_1-C_6 alkyl unsubstituted or substituted with one

(i) -OH, or

(ii) $-NH_2$,

(c) -C_1-C_6 alkyl unsubstituted or substituted with one to three -F, -Cl, -Br, or -I,

(d) -C_3-C_7 cycloalkyl,

(e) -(C_1-C_2 alkyl)-(C_3-C_7 cycloalkyl),

(f) -(C_1-C_6 alkyl)-O-(C_1-C_3 alkyl),

(g) -C_1-C_6 alkenyl with one or two double bonds,

(h) -C_1-C_6 alkynyl with one or two triple bonds,

(i) $-C_1-C_6$ alkyl chain with one double bond and one triple bond,

(j) $-R_{1\text{-aryl}}$ where $R_{1\text{-aryl}}$ is as defined above, or

(k) $-R_{1\text{-heteroaryl}}$ where $R_{1\text{-heteroaryl}}$ is as defined above,

(8) $-CO-(C_3-C_{12}$ alkyl),

(9) $-CO-(C_3-C_6$ cycloalkyl),

(10) $-CO-R_{1\text{-heteroaryl}}$ where $R_{1\text{-heteroaryl}}$ is as defined above,

(11) $-CO-R_{1\text{-heterocycle}}$ where $R_{1\text{-heterocycle}}$ is as defined above,

(12) $-CO-R_{N-4}$ where R_{N-4} is morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl or pyrrolidinyl where each group is unsubstituted or substituted with one or two C_1-C_3 alkyl,

(13) $-CO-O-R_{N-5}$ where R_{N-5} is:

(a) C_1-C_6 alkyl, or

(b) $-(CH_2)_{0-2}-(R_{1\text{-aryl}})$ where $R_{1\text{-aryl}}$ is as defined above,

(14) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are as defined above,

(15) $-SO-(C_1-C_8$ alkyl),

(16) $-SO_2-(C_3-C_{12}$ alkyl),

(17) $-NH-CO-O-R_{N-5}$ where R_{N-5} is as defined above,

(18) $-NH-CO-N(C_1-C_3$ alkyl$)_2$,

(19) $-N-CS-N(C_1-C_3$ alkyl$)_2$,

(20) $-N(C_1-C_3$ alkyl$)-CO-R_{N-5}$ where R_{N-5} is as defined above,

(21) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} can be the same or different and are as defined above,

(22) $-R_{N-4}$ where R_{N-4} is as defined above,

(23) $-O-CO-(C_1-C_6$ alkyl),

(24) $-O-CO-N(C_1-C_3$ alkyl$)_2$,

(25) $-O-CS-N(C_1-C_3$ alkyl$)_2$,

(26) $-O-(C_1-C_6$ alkyl),

(27) $-O-(C_2-C_5$ alkyl$)-COOH$,

(28) $-S-(C_1-C_6$ alkyl),

(29) C_1-C_6 alkyl unsubstituted or substituted with 1, 2, 3, 4, or 5 -F,

(30) $-O-(C_1-C_6$ alkyl unsubstituted or substituted with 1, 2, 3, 4, or 5 -F, or

(31) $-O-\phi$,

(B) $-R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is:

(A) pyridinyl,

(B) pyrimidinyl,

(C) quinolinyl,

(D) indenyl,

(E) indanyl,

(F) benzothiophenyl,

(G) indolyl,

(H) indolinyl,

(I) pyridazinyl,

(J) pyrazinyl,

(K) isoindolyl,

(L) isoquinolyl,

(M) quinazolinyl,

(N) quinoxalinyl,

(O) phthalazinyl,

(P) imidazolyl,

(Q) isoxazolyl,

(R) pyrazolyl,

(S) oxazolyl,

(T) thiazolyl,

(U) indolizinyl,

(V) indazolyl,

(W) benzothiazolyl,

(X) benzimidazolyl,

(Y) benzofuranyl,

(Z) furanyl,

(AA) thienyl,

(BB) pyrrolyl,

(CC) oxadiazolyl,

(DD) thiadiazolyl,

(EE) triazolyl,

(FF) tetrazolyl,

(GG) 1, 4-benzodioxan

(HH) purinyl,

(II) oxazolopyridinyl,

(JJ) imidazopyridinyl,

(KK) isothiazolyl,

(LL) naphthyridinyl,

(MM) cinnolinyl,

(NN) carbazolyl,

(OO) β-carbolinyl,

(PP) isochromanyl,

(QQ) chromanyl,

(RR) furazanyl,

(SS) tetrahydroisoquinoline,

(TT) isoindolinyl,

(UU) isobenzotetrahydrofuranyl,

(VV) isobenzotetrahydrothienyl,

(WW) isobenzothiophenyl,

(XX) benzoxazolyl, or

(YY) pyridopyridinyl,

where the $R_{N\text{-heteroaryl}}$ group is bonded by any atom of the parent $R_{N\text{-heteroaryl}}$ group substituted by hydrogen such that the new bond to the $R_{N\text{-heteroaryl}}$ group replaces the hydrogen atom and its bond, where heteroaryl is unsubstituted or substituted with one or two:

(1) C_1-C_6 alkyl,

(2) -F, -Cl, -Br, or - I,

(3) -OH,

(4) $-NO_2$,

(5) -CO-OH,

(6) -C≡N,

(7) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are:

(a) -H,

(b) -C_1-C_6 alkyl unsubstituted or substituted with one

(i) -OH, or

(ii) $-NH_2$,

(c) -C_1-C_6 alkyl unsubstituted or substituted with 1, 2, or 3 -F, -Cl, -Br, or -I,

(d) -C_3-C_7 cycloalkyl,

(e -(C_1-C_2 alkyl)-(C_3-C_7 cycloalkyl),

(f) -(C_1-C_6 alkyl)-O-(C_1-C_3 alkyl),

(g) -C_1-C_6 alkenyl with one or two double bonds,

(h) -C_1-C_6 alkynyl with one or two triple bonds,

(i) -C_1-C_6 alkyl chain with one double bond and one triple bond,

(j) -$R_{1\text{-aryl}}$ where $R_{1\text{-aryl}}$ is as defined above, or

(k) -$R_{1\text{-heteroaryl}}$ where $R_{1\text{-heteroaryl}}$ is as defined above,

(8) -CO-(C_3-C_{12} alkyl),

(9) -CO-(C_3-C_6 cycloalkyl),

(10) -CO-$R_{1\text{-heteroaryl}}$ where $R_{1\text{-heteroaryl}}$ is as defined above,

(11) -CO-$R_{1\text{-heterocycle}}$ where $R_{1\text{-heterocycle}}$ is as defined above,

(12) -CO-$R_{N\text{-}4}$ where $R_{N\text{-}4}$ is morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl or pyrrolidinyl where each group is unsubstituted or substituted with one or two C_1-C_3 alkyl,

(13) -CO-O-$R_{N\text{-}5}$ where $R_{N\text{-}5}$ is:

(a) C_1-C_6 alkyl, or

(b) -$(CH_2)_{0\text{-}2}$-($R_{1\text{-aryl}}$) where $R_{1\text{-aryl}}$ is as defined above,

(14) -SO_2-$NR_{N\text{-}2}R_{N\text{-}3}$ where $R_{N\text{-}2}$ and $R_{N\text{-}3}$ are as defined above,

(15) -SO-(C_1-C_8 alkyl),

(16) -SO_2-(C_3-C_{12} alkyl),

(17) $-NH-CO-O-R_{N-5}$ where R_{N-5} is as defined above,

(18) $-NH-CO-N(C_1-C_3 \text{ alkyl})_2$,

(19) $-N-CS-N(C_1-C_3 \text{ alkyl})_2$,

(20) $-N(C_1-C_3 \text{ alkyl})-CO-R_{N-5}$ where R_{N-5} is as defined above,

(21) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} can be the same or different and are as defined above,

(22) $-R_{N-4}$ where R_{N-4} is as defined above,

(23) $-O-CO-(C_1-C_6 \text{ alkyl})$,

(24) $-O-CO-N(C_1-C_3 \text{ alkyl})_2$,

(25) $-O-CS-N(C_1-C_3 \text{ alkyl})_2$,

(26) $-O-(C_1-C_6 \text{ alkyl})$,

(27) $-O-(C_2-C_5 \text{ alkyl})-COOH$, or

(28) $-S-(C_1-C_6 \text{ alkyl})$,

(C) $-R_{N-aryl}-R_{N-aryl}$ where $-R_{N-aryl}$ is as defined above,

(D) $-R_{N-aryl}-R_{N-heteroaryl}$ where $-R_{N-aryl}$ and $-R_{N-heteroaryl}$ are as defined above,

(E) $-R_{N-heteroaryl}-R_{N-aryl}$ where $-R_{N-aryl}$ and $-R_{N-heteroaryl}$ are as defined above,

(F) $-R_{N-heteroaryl}-R_{N-heteroaryl}$ where $R_{N-heteroaryl}$ is as defined above,

(G) $-R_{N-aryl}-O-R_{N-aryl}$ where $-R_{N-aryl}$ is as defined above,

(H) $-R_{N-aryl}-S-R_{N-aryl}$ where $-R_{N-aryl}$ is as defined above,

(I) $-R_{N-heteroaryl}-O-R_{N-heteroaryl}$ where $R_{N-heteroaryl}$ is as defined above,

(J) $-R_{N\text{-heteroaryl}}-S-R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is as defined above,

(K) $-R_{N\text{-aryl}}-CO-R_{N\text{-aryl}}$ where $-R_{N\text{-aryl}}$ is as defined above,

(L) $-R_{N\text{-aryl}}-CO-R_{N\text{-heteroaryl}}$ where $-R_{N\text{-aryl}}$ and $R_{N\text{-heteroaryl}}$ are as defined above,

(M) $-R_{N\text{-aryl}}-SO_2-R_{N\text{-aryl}}$ where $-R_{N\text{-aryl}}$ is as defined above,

(N) $-R_{N\text{-heteroaryl}}-CO-R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is as defined above,

(O) $-R_{N\text{-heteroaryl}}-SO_2-R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is as defined above,

(P) $-R_{N\text{-aryl}}-O-(C_1-C_8\ \text{alkyl})-\phi$ where $R_{N\text{-aryl}}$ is as defined above,

(Q) $-R_{N\text{-aryl}}-S-(C_1-C_8\ \text{alkyl})-\phi$ where $R_{N\text{-aryl}}$ is as defined above,

(R) $-R_{N\text{-heteroaryl}}-O-(C_1-C_8\ \text{alkyl})-\phi$ where $R_{N\text{-heteroaryl}}$ is as defined above, or

(S) $-R_{N\text{-heteroaryl}}-S-(C_1-C_8\ \text{alkyl})-\phi$ where $R_{N\text{-heteroaryl}}$ is as defined above,

(II) $A-X_N-$ where X_N is $-CO-$,

wherein A is

(A) $-T-E-(Q)_{m'}$,

(1) where -T is



where

(a) x =1 when y = 1 and x = 2 when y = 0,

(b) m is 0, 1, 2 or 3,

(c) the values of x and y vary independently on each carbon when m is 2 and 3, and

(d) R''' varies independently on each carbon and is H, (C_1-C_2) alkyl, phenyl, or phenyl(C_1-C_3)alkyl;

(2) -E is

(a) C_1-C_5 alkyl, but only if m' does not equal 0,

(b) methylthioxy(C_2-C_4)alkyl,

(c) an aryl group having 5 to 7 atoms when monocyclic or having 8 to 12 atoms when fused,

(d) a heterocyclic group having 5 to 7 atoms when monocyclic or having 8 to 12 atoms when fused,

(e) a mono or fused ring cycloalkyl group having 5 to 10 carbon atoms,

(f) biphenyl,

(g) diphenyl ether,

(h) diphenylketone,

(i) phenyl(C_1-C_8)alkyloxyphenyl, or

(j) C_1-C_6 alkoxy;

(3) -Q is

(a) C_1-C_3 alkyl,

(b) C_1-C_3 alkoxy,

(c) C_1-C_3 alkylthioxy,

(d) C_1-C_6 alkylacylamino,

(e) C_1-C_6 alkylacyloxy,

(f) amido (including primary, C_1-C_6 alkyl and phenyl secondary and tertiary amino moieties),

(g) C_1-C_6 alkylamino

(h) phenylamino,

(i) carbamyl (including C_1-C_6 alkyl and phenyl amides and esters),

(j) carboxyl (including C_1-C_6 alkyl and phenyl esters),

(k) carboxy(C_2-C_5)alkoxy,

(l) carboxy(C_2-C5)alkylthioxy,

(m) heterocyclylacyl,

(n) heteroarylacyl, or

(o) hydroxyl;

(4) m' is 0, 1, 2 or 3;

(B) $-E(Q)_{m''}$ wherein E and -Q are as defined as above and m" is 0, 1, 2, or 3;

(C) -T-E wherein -E and -Q are as defined as above; or

(D) -E wherein -E is as defined as above;

(III) -CO-(C_1-C_6 alkyl) where alkyl is unsubstituted or substituted with one or two:

(A) -OH,

(B) -C_1-C_6 alkoxy,

(C) -C_1-C_6 thioalkoxy,

(D) $-CO-O-R_{N-8}$ where R_{N-8} is -H, C_1-C_6 alkyl or -ϕ,

(E) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(F) $-CO-R_{N-4}$ where R_{N-4} is as defined above,

(G) $-SO_2-(C_1-C_8$ alkyl),

(H) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(I) $-NH-CO-(C_1-C_6$ alkyl),

(J) $-NH-CO-O-R_{N-8}$ where R_{N-8} is as defined above,

(K) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(L) $-R_{N-4}$ where R_{N-4} is as defined above,

(M) $-O-CO-(C_1-C_6$ alkyl),

(N) $-O-CO-NR_{N-8}R_{N-8}$ where the R_{N-8} is the same or different and are as defined above, or

(O) $-O-(C_1-C_5$ alkyl)-COOH,

(IV) $-CO-(C_1-C_3$ alkyl)$-O-(C_1-C_3$ alkyl) where alkyl is unsubstituted or substituted with one or two

(A) -OH,

(B) $-C_1-C_6$ alkoxy,

(C) $-C_1-C_6$ thioalkoxy,

(D) $-CO-O-R_{N-8}$ where R_{N-8} is -H, C_1-C_6 alkyl or $-\phi$,

(E) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(F) $-CO-R_{N-4}$ where R_{N-4} is as defined above,

(G) $-SO_2-(C_1-C_8$ alkyl),

(H) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(I) $-NH-CO-(C_1-C_6$ alkyl),

(J) $-NH-CO-O-R_{N-8}$ where R_{N-8} is as defined above,

(K) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(L) $-R_{N-4}$ where R_{N-4} is as defined above,

(M) $-O-CO-(C_1-C_6$ alkyl),

(N) $-O-CO-NR_{N-8}R_{N-8}$ where the R_{N-8} are the same or different and are as defined above, or

(O) $-O-(C_1-C_5$ alkyl$)-COOH$,

(V) $-CO-(C_1-C_3$ alkyl$)-S-(C_1-C_3$ alkyl) where alkyl is unsubstituted or substituted with one or two

(A) $-OH$,

(B) $-C_1-C_6$ alkoxy,

(C) $-C_1-C_6$ thioalkoxy,

(D) $-CO-O-R_{N-8}$ where R_{N-8} is $-H$, C_1-C_6 alkyl or $-\phi$,

(E) $-CO-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(F) $-CO-R_{N-4}$ where R_{N-4} is as defined above,

(G) $-SO_2-(C_1-C_8$ alkyl$)$,

(H) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(I) $-NH-CO-(C_1-C_6$ alkyl$)$,

(J) $-NH-CO-O-R_{N-8}$ where R_{N-8} is as defined above,

(K) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are the same or different and are as defined above,

(L) $-R_{N-4}$ where R_{N-4} is as defined above,

(M) $-O-CO-(C_1-C_6$ alkyl$)$,

(N) $-O-CO-NR_{N-8}R_{N-8}$ where the R_{N-8} are the same or different and are as defined above, or

(O) $-O-(C_1-C_5$ alkyl$)-COOH$,

(VI) $-CO-CH(-(CH_2)_{0-2}-O-R_{N-10})-(CH_2)_{0-2}-R_{N\text{-}aryl}/R_{N\text{-}heteroaryl})$ where R_{N-aryl} and $R_{N-heteroaryl}$ are as defined above, where R_{N-10} is:

(A) $-H$,

(B) C_1-C_6 alkyl,

(C) C_3-C_7 cycloalkyl,

(D) C_2-C_6 alkenyl with one double bond,

(E) C_2-C_6 alkynyl with one triple bond,

(F) $R_{1\text{-aryl}}$ where $R_{1\text{-aryl}}$ is as defined above, or

(G) $R_{N\text{-heteroaryl}}$ where $R_{N\text{-heteroaryl}}$ is as defined above;

where B is -O-, -NH-, or -N(C_1-C_6 alkyl)-;

where R_C is: -$(CH_2)_{0-3}$-(C_3-C_7) cycloalkyl where cycloalkyl can be unsubstituted or substituted with one, two or three

(A) C_1-C_3 alkyl unsubstituted or substituted with 1, 2, 3, or 4 -F,

-Cl, -Br, or -I,

(B) -CO-OH,

(C) -CO-O-(C_1-C_4 alkyl),

(D) -OH, or

(E) C_1-C_6 alkoxy,

or a pharmaceutically acceptable salt thereof.

Claim 50. (currently amended) The method of claim 49, wherein said compound inhibits 50% of β-secretase ~~the enzyme's~~ activity at a concentration of from about 0.1nM to about 200μM.

Claim 51. (currently amended) The method of claim 50, wherein said compound inhibits 50% of β-secretase ~~the enzyme's~~ activity at a concentration of from about 10nM to about 100μM.

Claim 52. (currently amended) The method of claim 51, wherein said compound inhibits 50% of β-secretase ~~the enzyme's~~ activity at a concentration of from about 100nM to about 50μM.

Claim 53. (currently amended) The method of claim 52, wherein said compound inhibits 50% of β-secretase ~~the enzyme's~~ activity at a concentration of from about 1μM to about 10μM.

Claim 54. (previously presented) The method of claim 49, wherein said therapeutic amount is in the range of from about 0.1 to about 1000 mg/day.

Claim 55. (previously presented) The method of claim 49, wherein said therapeutic amount is in the range of from about 15 to about 1500 mg/day.

Claim 56. (previously presented) The method of claim 55, wherein said therapeutic amount is in the range of from about 1 to about 100 mg/day.

Claim 57. (previously presented) The method of claim 56, wherein said therapeutic amount is in the range of from about 5 to about 50 mg/day.

Claims 58-93(cancelled)

Claim 94. (previously presented) A method according to claim 49, wherein the compound is

N-[(1*S*, 2*S*, 4*R*)-1-(3,5-Difluorobenzyl)-4-(*syn*, *syn*)-(3,5 dimethoxycyclohexylcarbamoyl)-2-hydroxyhexyl]-*N*,*N*-dipropylisophathalamide;

N-[4-(*R*)-(Cyclohexylmethyl-carbamoyl)-1-(*S*)-(3,5-difluoro-benzyl)-2-(*S*)-hydroxy-hexyl]-*N*,*N*-dipropyl-isophthalamide;

4-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid methyl ester;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxy-2-(*R*)-methyl-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxy-2-(*R*)-propyl-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxyl-2-(*R*)-isobutyl-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([2-(*R*)-Benzyl-6-(3,5-difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-benzoylamino)-4-(*S*)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-5-methyl-benzoylamino)-2-(*R*)-ethyl-4-(S)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid;

4-(*anti*)-([6-(3,5-Difluoro-phenyl)-5-(*S*)-(3-dipropylcarbamoyl-5-methyl-benzoylamino)-2-(*R*)-ethyl-4-(S)-hydroxy-hexanoylamino]-methyl)-cyclohexanecarboxylic acid methyl ester;

4-(*anti*)-{[6-(3,5-Difluorophenyl)-5-(*S*)-(3-dipropylcarbamoylbenzoylamino)-2-(*R*)-ethyl-4-(*S*)-hydroxyhexanoylamino]-methyl}cyclohexanecarboxylic acid;

N-[(1*S*, 2*S*, 4*R*)-1-(3,5-Difluorobenzyl)-4-(*syn*,*syn*)-(3,5-dimethoxycyclohexylcarbamoyl)-2-hydroxyhexyl]-*N*,*N*-dipropylisophathalamide; or

N-[4-(*R*)-(Adamantan-2-ylcarbamoyl)-1-(*S*)-(3,5-difluoro-benzyl)-2-(*S*)-hydroxy-pentyl]-5-methyl-*N*,*N*-dipropyl-isophthalamide.

Claims 95-104. (cancelled)